China’s National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Soliris (eculizumab) to treat refractory generalised myasthenia gravis (gMG) in adult patients.
Soliris is a first-in-class C5 complement inhibitor indicated for patients who are anti-acetylcholine receptor (AChR) antibody-positive.
It inhibits the C5 protein in the terminal complement cascade, part of the body’s immune system.
The therapy has already been approved to treat atypical haemolytic uraemic syndrome, paroxysmal nocturnal haemoglobinuria and certain gMG adult patients in the US, Japan, the EU and China.
It has also been approved for the treatment of adults with neuromyelitis optica spectrum disorder in the US, Japan and the EU.
AstraZeneca’s subsidiary Alexion CEO Marc Dunoyer stated: “Symptoms of gMG, including difficulties seeing, walking, talking, swallowing and breathing, can have a debilitating impact on daily life for patients and their families, representing a critical need for therapeutic advances.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We are proud to offer Soliris in China, a first-in-class C5 complement inhibitor and a globally established treatment for gMG.
“We remain committed to expanding access to innovative therapies for rare disease patients in China and around the world.”
The regulatory approval was based on comprehensive data obtained from the Phase III REGAIN trial conducted in 125 patients across South America, North America, Europe and Asia.
The 26-week placebo-controlled, randomised, double-blind, multicentre trial was designed to assess Soliris’s efficacy and safety in refractory gMG adult patients.
The findings showed the clinical benefit of Soliris for anti-AChR antibody-positive gMG patients who had previously failed to progress on immunosuppressive treatment and continued to have significant unresolved disease symptoms.
The therapy’s tolerability and safety profile were found to be consistent throughout the primary treatment period, as well as the open-label extension.
Upper respiratory tract infection and headache were the most common adverse events observed in the primary treatment period.
